NCT04203719 - A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

May 9, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

May 30, 2021

Conditions

Advanced Head, Neck and Chest Cancer

Interventions

DRUG

AK105

AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.

DRUG

Anlotinib

a multi-target receptor tyrosine kinase inhibitor

Trial Locations (1)

100021

RECRUITING

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing